On Tuesday, Pfizer Inc. PFE released its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion compared to a consensus of $63.28 billion.For 2025, Pfizer expects revenue from COVID-19 products to remain consistent with 2024, excluding approximately $1.2 billion in one-time Paxlovid revenue recognized in 2024.The guidance accounts for an estimated $1 billion net unfavorable revenue impact due to changes under the Inflation Reduction Act (IRA), particularly Medicare Pa ...

Core Insights - Pfizer Inc. is set to conduct an investor call to provide full-year 2025 financial guidance, with Goldman Sachs outlining expectations for the guidance and commentary on the upcoming year [1] - The analyst anticipates Pfizer's management will guide to EPS in the mid-to-high $2 range, with core business growth offset by $0.30 in favorable but non-recurring items during 2024 [1] Financial Projections - Pfizer's 2024 EPS includes one-time boosts such as a $1.2 billion benefit from Paxlovid stockpiling and U.S. government true-up, which will not carry over to 2025 due to a decrease in ownership in Haleon Plc [2] - Goldman Sachs forecasts 2025 revenues of $64.9 billion and EPS of $3.13, compared to consensus estimates of $63.2 billion and $2.89, respectively [2] Sales Expectations - The impact of the IRA Part D redesign is expected to be addressed in the 2025 guidance, though details may not be broken down by individual products [3] - Expected Paxlovid sales for 2025 are projected at $4.3 billion, exceeding consensus of $3.7 billion, while Vyndaqel sales are forecasted at $5.9 billion, slightly below consensus of $6.2 billion [3] Market Performance - Eliquis has shown 12% growth year-to-date, supported by market expansion and increased market share, with expectations for continued growth opportunities in 2025 [4] - Pfizer's commercial team has played a significant role in this growth, aided by Part D catastrophic coverage in 2024 [4] Industry Context - Goldman Sachs highlights that Pfizer is the only large-cap pharma company expected to provide insights on 2025 ahead of the new year, indicating potential broader implications for the industry [5] Stock Performance - As of the latest check, PFE stock is down 0.39% at $25.48 [6]

I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking AlphaAnalyst’s Disclosure: I/we have a beneficial long position in the shares of PFE, ABBV e ...

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these companies generally see at least stability in revenue. But it's important to note that you can turn to these players for growth too.Drugmakers often see phases of growth as they develop candidates for a high-potential treatment area or as they launch promising new products. Over time, you can benefit from these ...

With a market capitalization of more than $143 billion today, Pfizer (PFE 0.83%) stock won't make anyone into a millionaire unless they're willing to commit a large amount of capital and then hold the stock for a very long period of time, reinvesting all the dividends they receive along the way. Big pharma businesses simply don't grow quickly enough to deliver investors the massive returns that are necessary to generate millions from a humble starting sum.There's no evidence that Pfizer is about to change i ...

Pfizer (PFE) closed the latest trading day at $25.23, indicating a -1.33% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.82%. Meanwhile, the Dow lost 0.22%, and the Nasdaq, a tech-heavy index, added 1.77%.The the stock of drugmaker has fallen by 2.37% in the past month, leading the Medical sector's loss of 4.06% and undershooting the S&P 500's gain of 0.8%.Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upco ...

Retirement is complicated and you only get once chance to do it right. Don't miss out because you didn't know what was out there.The Retirement Forum provides actionable ideals, a high-yield safe retirement portfolio, and macroeconomic outlooks, all to help you maximize your capital and your income. We search the entire market to help you maximize returns.Pfizer (NYSE: PFE ) is one of the largest pharmaceutical companies in the world. However, its share price has continued to struggle since our last recomme ...

Now you can get access to the latest and highest-quality analysis of recent Wall Street buying and selling ideas with just one subscription to Beyond the Wall Investing ! There is a free trial and a special discount of 10% for you. Join us today!I reinitiated my coverage of Pfizer Inc. (NYSE: PFE ) (NEOE: PFE:CA ) stock at the end of December 2023 with a "Buy" rating, when the stock was trading at $27.86 apiece. Since then, I have published 4 more bullishDaniel Sereda is chief investment analyst at a family ...

Pfizer's (PFE) stock has declined 7.8% in the past month. Though the stock has been affected by declining sales of its COVID products, a lot of this stock price decline could be due to the broader drug/biotech sector's decline in the past month. Lower-than-expected sales of Lilly (LLY) and Novo Nordisk's (NVO) popular diabetes and obesity drugs in the third quarter, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as head of Health and Human Services (HHS) ha ...

Things aren't getting much better for Pfizer (PFE -1.29%). The company is still suffering from the significant drop in sales of its coronavirus products and the less-than-impressive financial results it has produced during the past two years. And although Pfizer's revenue is growing again, that's not enough for the drugmaker to get back in the good graces of investors. Pfizer has, unquestionably, made progress. Many new approvals and acquisitions have expanded its lineup and pipeline. However, it's fair to ...